Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C

• Published in: Journal of gastroenterology 2014-08, Vol.49 (8), p.1253-1263
• Main Authors: Aizawa, Nobuhiro, Enomoto, Hirayuki, Takashima, Tomoyuki, Sakai, Yoshiyuki, Iwata, Kazunari, Ikeda, Naoto, Tanaka, Hironori, Iwata, Yoshinori, Saito, Masaki, Imanishi, Hiroyasu, Iijima, Hiroko, Nishiguchi, Shuhei
• Format: Article
• Language: English
• Subjects: Abdominal Surgery; Aged; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Biliary Tract; Biological response modifiers; Care and treatment; Colorectal Surgery; Drug Therapy, Combination; Embolization, Therapeutic - methods; Female; Gastroenterology; Genotype; Health aspects; Hepacivirus - genetics; Hepatitis C virus; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; Hepatology; Humans; Interferon; Interferon alpha-2; Interferon-alpha - administration & dosage; Interferon-alpha - therapeutic use; Interferons; Interleukins - genetics; Liver; Liver cirrhosis; Liver Cirrhosis - drug therapy; Liver Cirrhosis - virology; Male; Medicine; Medicine & Public Health; Middle Aged; Original Article—Liver; Original —Liver, Pancreas, and Biliary Tract; Pancreas; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - therapeutic use; Prognosis; Recombinant Proteins - administration & dosage; Recombinant Proteins - therapeutic use; Ribavirin; Ribavirin - administration & dosage; Ribavirin - therapeutic use; Spleen - pathology; Spleen - surgery; Splenectomy - methods; Surgical Oncology; Thrombocytopenia; Thrombocytopenia - physiopathology; Treatment Outcome
• ISSN: 0944-1174; 1435-5922
• DOI: 10.1007/s00535-013-0884-0

Background This study aimed to examine the therapeutic effect and prognostic indicators of pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy in thrombocytopenic patients with chronic hepatitis C, hepatitis C virus (HCV)-related cirrhosis, and those who underwent splenectomy or partial splenic embolization (PSE). Methods Of 326 patients with HCV-related chronic liver disease (252 with genotype 1b and 74 with genotype 2a/2b) treated with PEG-IFN/RBV, 90 were diagnosed with cirrhosis. Results Regardless of the degree of thrombocytopenia, the administration rate was significantly higher in the splenectomy/PSE group compared to the cirrhosis group. However, in patients with genotype 1b, the sustained virological response (SVR) rate was significantly lower in the cirrhosis and the splenectomy/PSE groups compared to the chronic hepatitis group. No cirrhotic patients with platelets less than 80,000 achieved an SVR. Patients with genotype 2a/2b were more likely to achieve an SVR than genotype 1b. Prognostic factors for SVR in patients with genotype 1b included the absence of esophageal and gastric varices, high serum ALT, low AST/ALT ratio, and the major homo type of the IL28B gene. Splenectomy- or PSE-facilitated induction of IFN in patients with genotype 2a/2b was more likely to achieve an SVR by an IFN dose maintenance regimen. Patients with genotype 1b have a low SVR regardless of splenectomy/PSE. In particular, patients with a hetero/minor type of IL28B did not have an SVR. Conclusions Splenectomy/PSE for IFN therapy should be performed in patients expected to achieve a treatment response, considering their genotype and IL28B.